Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Common Equity (2017 - 2022)

Historic Common Equity for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $32.5 million.

  • Iterum Therapeutics' Common Equity fell 3794.04% to $32.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $32.5 million, marking a year-over-year decrease of 3794.04%. This contributed to the annual value of $50.2 million for FY2021, which is 19935.72% up from last year.
  • As of Q3 2022, Iterum Therapeutics' Common Equity stood at $32.5 million, which was down 3794.04% from $43.9 million recorded in Q2 2022.
  • Iterum Therapeutics' 5-year Common Equity high stood at $118.5 million for Q2 2018, and its period low was -$55.9 million during Q3 2020.
  • Its 5-year average for Common Equity is $24.5 million, with a median of $38.2 million in 2022.
  • In the last 5 years, Iterum Therapeutics' Common Equity crashed by 170565.25% in 2020 and then soared by 19935.72% in 2021.
  • Over the past 5 years, Iterum Therapeutics' Common Equity (Quarter) stood at $71.6 million in 2018, then plummeted by 136.63% to -$26.2 million in 2019, then plummeted by 92.69% to -$50.6 million in 2020, then soared by 199.36% to $50.2 million in 2021, then plummeted by 35.21% to $32.5 million in 2022.
  • Its last three reported values are $32.5 million in Q3 2022, $43.9 million for Q2 2022, and $48.6 million during Q1 2022.